Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ch128.1
- Development stage
- Preclinical
- Lead developer
- University of California, Los Angeles
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Parenteral
01
Overview
ch128.1 is a mouse/human chimeric IgG3 monoclonal antibody that targets the human transferrin receptor 1 (TfR1), also known as CD71. Developed by researchers at UCLA, the antibody is designed to treat hematopoietic malignancies, particularly multiple myeloma. Its mechanism of action involves direct cytotoxicity through the induction of TfR1 degradation and subsequent lethal iron deprivation in malignant cells. Additionally, ch128.1 elicits Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), primarily mediated by macrophages in vivo. While it can bind C1q and induce complement-mediated cytotoxicity (CDC) in vitro, studies suggest CDC may not be the primary driver of its anti-tumor activity in xenograft models.
- Other names
- ch128.1 IgG3ch-128.1 IgG3ch 128.1 IgG3anti-TfR1 chimeric antibodyanti-TfR-1 chimeric antibodyanti-TfR 1 chimeric antibody
02
Targets
TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on ch128.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ch128.1.